Trending News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

Biden to invest US$3 bn to boost Covid-19 drug discovery

As part of the American Rescue Plan, the Biden Administration is investing more than US$3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the whole-of-government strategy to develop the next generation of Covid-19 treatments. Through collaboration within the US Department of Health and Human… Read More

#News #Trending News

#Clinical trials #Covid-19 #CureVac #Immunology / Virology & Vaccines

CureVac mRNA vaccine only 47% effective

CureVac has announced results of the second interim analysis of its international pivotal Phase IIb/III study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation Covid-19 vaccine candidate, CVnCoV. At second interim analysis, statistical success criteria were not met. In the unprecedented context of at least 13 variants circulating… Read More

#Covid-19 #News #Trending News

#AstraZeneca #Biopharmaceuticals #Covid-19 #Immunology / Virology & Vaccines

AstraZeneca vaccine is 92% effective against Delta variant

New data from Public Health England (PHE) demonstrated AstraZeneca’s Covid-19 vaccine offers high levels of protection against the Delta variant (B.1.617.2; formerly the ‘Indian’ variant). Real world data from PHE, published as a pre-print, demonstrated two doses of AstraZeneca are 92% effective against hospitalisation due to the Delta variant and… Read More

#Covid-19 #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Public health #Sinovac #Vaccines

Has China approved a Covid-19 vaccine for three year olds?

The New York Times has reported that the Chairman of the Chinese drug maker Sinovac said China had approved the company’s Covid-19 vaccine for children as young as three, which the media outlet explains would make the country the first in the world to endorse a vaccine for children of… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug discovery

Aspirin does not improve survival for Covid-19 patients

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with Covid-19, who are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Pfizer #Vaccine candidate

Can Pfizer-BioNTech vaccine target the Delta variant?

Levels of antibodies in the blood of vaccinated people that can recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug development #Immunology / Virology & Vaccines

Is a needle-free Covid-19 vaccination possible?

University of Queensland scientists have successfully protected mice from the Covid-19 virus by administering a US-developed vaccine candidate with a ‘patch’, rather than a needle. The University of Texas Hexapro vaccine candidate, delivered via the UQ-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP), provided protection against Covid-19 disease with a single,… Read More

#Covid-19 #News #Trending News

#Cancer immunotherapy #Cancer research #Drug development

Are women less susceptible to some skin cancers?

Women may have a stronger immune response to a common form of skin cancer than men, according to early research on mice and human cells. Led by University of Manchester scientists at the Cancer Research UK Manchester Institute, the team publish their findings in Clinical Cancer Research. Men have more… Read More

#Cancer Research #News #Trending News

#Clinical trial #Clinical Trial Authorisation #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna initiates rolling submission of Biologics License Application (BLA)

Moderna has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for the licensure of its mRNA COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older. Stéphane Bancel, Chief Executive Officer of Moderna, said: “We look forward… Read More

#News #Trending News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna

Moderna Covid-19 vaccine safe and effective in teens

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19… Read More

#Covid-19 #News #Trending News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Epidemiology #Immunology / Virology & Vaccines #Pfizer

Pfizer launches Vaccine Centre of Excellence

Pfizer has launched a Centre of Excellence for Epidemiology of Vaccine-preventable Diseases at the University of Bristol. The centre, which is the second to launch to date and the first outside the US, will be led by Adam Finn, Professor of Paediatrics at Bristol, Director of the Bristol Vaccine Centre… Read More

#News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

Royal visit to celebrate key role in vaccine development

Malvern Panalytical, experts in high-precision analytical instruments, welcomed His Royal Highness The Earl of Wessex, Prince Edward, to its Worcestershire headquarters. Malvern Panalytical was selected for the Royal visit, amongst a small number of other Worcestershire businesses, primarily because of its scientific and technical contribution to the development of medicines… Read More

#News #Trending News

#Biotechnology #Diagnostics #Drug discovery #Immunology #Immunology / Virology & Vaccines #Pandemic

University of Oxford to launch Pandemic Sciences Centre

The University of Oxford has announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. Read More

#News #Trending News

Patient receiving vaccine
#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccines

Sanofi and GSK Covid-19 vaccine to progress to Phase III trials

The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralising antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a Phase II study with 722 volunteers. The Phase II interim results showed 95% to 100%… Read More

#Covid-19 #News #Trending News

Covid-19
#Cancer #Cancer research #Covid-19 #Drug repurposing

Can this cancer drug treat severe cases of Covid-19?

Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory gene has reduced morbidity and mortality in mice infected with SARS-CoV-2. In a study published in Cell, the team reported that the drug, topotecan (TPT), inhibited the expression of inflammatory genes in the lungs of mice… Read More

#Covid-19 #News #Trending News